Hail First Pharma Signs Buy-Out Extension Agreement
March 16 2011 - 10:46AM
Marketwired
Hail First Pharma Inc., a subsidiary of Al-Dorra Holdings, a
privately held Kuwaiti company, announced today that it has granted
an extension to the closing of the buy-out transaction with Spencer
Pharmaceutical Inc.(PINKSHEETS: SPPH).
According to the Extension Agreement, Al-Dorra and/or its
subsidiary will fund the animal studies and operational expenses in
the amount of $1.2 million USD. This extension is granted to
Spencer Pharmaceutical to allow a complete release of the analysis
by the independent research organization on the drug delivery
platform. The companies have agreed to postpone the closing to the
second quarter of 2011. Shareholders, representing over 55% of the
total outstanding of Spencer Pharmaceuticals, have already agreed
to tender their shares in favor of the transaction.
Hail First Pharma has also delayed its IPO to the second quarter
of 2011 due to current market turmoil, although a strong commitment
has already been receive from several institutional investors.
"The delay should not be viewed as a negative thing, since we
are only granting this delay to comply with disclosure requirements
and we do not want to appear to be hiding results from
shareholders," said Hussain Al-Awaid, Chairman of Hail First Pharma
Inc. "The various technologies acquired and companies will truly
create a leading pharmaceutical for our shareholders," further
added Al-Awaid.
Important Information About
Forward-Looking Statements in this press release may be
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as
"anticipate," "believe," "estimate," "expect," "intend" and similar
expressions, as they relate to the company or its management,
identify forward-looking statements. These statements are based on
current expectations, estimates and projections about the company's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and probably will,
differ materially from what is expressed or forecasted in such
forward-looking statements due to numerous factors, including those
described above. In addition, such statements could be affected by
risks and uncertainties related to the exploration for and
development of mineralized material, product demand, market and
customer acceptance, competition, pricing and development
difficulties, as well as general industry and market conditions and
growth rates and general economic conditions. Any forward-looking
statements speak only as of the date on which they are made, and
the company does not undertake any obligation to update any
forward-looking statement to reflect events or circumstances after
the date of this release. Information on the Company's website does
not constitute a part of this release.
Contact: Hussain Al-Awaid Tel +971-5061-25585
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Historical Stock Chart
From Nov 2023 to Nov 2024